Price$30.60-0.84 (-2.67%)
01:30 PM07:45 PM
News · 26 weeks60-36%
2026-01-182026-07-12
Mix3490d
- SEC Filings22(65%)
- Other11(32%)
- Analyst1(3%)
Latest news
25 items- PRSmith+Nephew introduces groundbreaking LYNX™ COBLATION™ Laryngeal Wand for ENT surgeonsDelivering versatility for airway procedures in a single, streamlined surgical solution Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, today announces the commercial launch of its LYNX COBLATION Laryngeal Wand, a multi-purpose solution designed by laryngologists for laryngology. Backed by surgeon insights and the need for versatility, the LYNX Wand is designed with a long working length and also fine dissection and mass debulking capabilities to support procedures from supraglottis to trachea1,2 at low temperatures*3 with reduced risk of airway fire.†4-6 The LYNX COBLATION Laryngeal Wand advances airway procedural solutions thanks to several key differentiators,
- PRNew German expert consensus provides first risk-based recommendations for sNPWT use in closed surgical incisionsSmith+Nephew ((LSE: SN, NYSE:SNN), the global medical technology company, today announces the publication of new consensus-based guidance - developed independently by expert clinicians for the use of single-use negative pressure wound therapy (sNPWT) in closed surgical incisions. The guidance is supported by practical clinical practice recommendations for Germany. Published in internationally recognised journal of surgery Die Chirurgie, the new German consensus was supported by Smith+Nephew, a pioneer in sNPWT and manufacturer of the PICO™7 sNPWT system. New consensus provides practical framework for post-surgical careThis new interdisciplinary consensus is the first in Germany to translate
- PRNew German expert consensus highlights role for NPWT in mitigating the economic impact of postoperative wound complicationsSmith+Nephew ((LSE: SN, NYSE:SNN), the global medical technology company, today announces the publication by expert clinicians of new consensus-based guidance - developed by them for the use of single-use negative pressure wound therapy (sNPWT) in closed surgical incisions. The guidance is supported by practical clinical practice recommendations for Germany and has been published in the internationally recognised journal of surgery Die Chirurgie. The new German consensus was supported by Smith+Nephew, a pioneer in sNPWT and manufacturer of the PICO™7 sNPWT system. New guidelines link prevention strategies to improved health economics A recently published interdisciplinary expert consensus s
- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
- PRFresh Off Its Nasdaq Debut, a Regenerative-Medicine Upstart Is Stacking Its Board With Big-Pharma FirepowerIssued on behalf of Conexeu Sciences Inc.A clutch of new directors with Fortune 500 finance, M&A, and aesthetics pedigrees signals that the newly public tissue-regeneration company is building for commercialization — in one of medicine's most consequential frontiers.RENO, Nev., June 16, 2026 /CNW/ -- American News Group News Commentary — There is a well-worn pattern in the life sciences: a company spends years on the science, goes public, and then — in the critical window right after listing — races to assemble the kind of leadership bench that can turn a promising platform into a real business. The names a young company recruits in that window say a great deal about its ambitions. On June 1
- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
- PRA Fresh FDA Catalyst Is Putting Regenerative Wound Care in FocusNEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Equity Insider News Commentary — In healthcare, the market tends to perk up when a company stops speaking in broad platform language and starts showing real progress toward the FDA. That is what makes the latest update from Conexeu Sciences Inc. (NASDAQ:CNXU) — issued from Reno, Nevada on June 8, 2026 — worth a closer look. A newly Nasdaq-listed regenerative-tissue company carrying a market capitalization in the hundreds of millions, Conexeu has moved its lead CXU™ wound-care program further into manufacturing scale-up and regulatory preparation as it works toward a planned first-quarter 2027 510(k) submission. Companies mentioned: Conexeu Scien
- PRSmith+Nephew announces first clinical cases with the next generation CORI◊XT Handheld Robotics Platform across knee and shoulder arthroplastySmith+Nephew ((LSE: SN, NYSE:SNN), the global medical technology company, announces the completion of the first clinical cases performed using the next‑generation CORI◊ XT Handheld Robotics Platform, marking an important milestone in the clinical introduction of its latest handheld robotics technology. CORI XT Handheld Robotic Platform is designed to be the single handheld robotics platform for all orthopaedic needs - partial to revision knee, hip*, and anatomic and reverse shoulders - with a footprint tailored to the unique needs of hospitals and ambulatory surgical suites settings. These early cases represent the first use of CORI XT Platform across both knee and shoulder arthroplasty a
- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
- ANALYSTSmith & Nephew downgraded by KeplerKepler downgraded Smith & Nephew from Buy to Hold
- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
- PRSmith+Nephew launch next generation LEAF™ Patient Monitoring System – an innovative pressure injury prevention platform delivering proven clinical impactSmith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, announces the US launch of next generation LEAF♢ Patient Monitoring System, a data-driven pressure injury prevention platform designed to help health care providers tackle the growing burden of hospital-acquired pressure injuries (HAPIs) by strengthening protocols and outcomes. The LEAF System uses a wearable sensor to monitor patient mobility and provide real-time turn status updates, helping to improve workflow efficiency, turn quality, and protocol adherence.1-3 Every year, approximately 60,000 annual deaths in the US are attributed to HAPIs,4 placing a $26.8B annual burden on the nationwide economy.5 For individu
- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
- PRA Reno Biotech Just Rang the Nasdaq Bell — Here's Why the Whole Regenerative-Medicine Tape Is Worth WatchingFive companies. One overlapping story. The race to rebuild human tissue is moving from the lab into the public markets — fast. NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- World Street Intelligence News Commentary — There are weeks when the most interesting story on Wall Street isn't a single ticker. It's the through-line connecting several of them. The week of May 21, 2026 was one of those weeks. A brand-new Nasdaq listing in regenerative tissue arrived in the middle of a cluster of earnings beats, pipeline launches, and product approvals across a handful of related names — all of them, in one way or another, telling the same story: medicine is shifting from "replace" to "regenerate," and
- SECSEC Form SD filed by Smith & Nephew SNATS Inc.SD - SMITH & NEPHEW PLC (0000845982) (Filer)
- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
- SECSEC Form 6-K filed by Smith & Nephew SNATS Inc.6-K - SMITH & NEPHEW PLC (0000845982) (Filer)
SNN FAQ
7 questionsWhat does Smith & Nephew SNATS Inc. do?
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as...Where does SNN stock trade?
Smith & Nephew SNATS Inc. (SNN) is listed on NYSE.What sector and industry is SNN in?
Smith & Nephew SNATS Inc. operates in the Health Care sector, Industrial Specialties industry.Does SNN pay a dividend?
SNN's most recent ex-dividend date was 2026-03-27 with a cash dividend of $0.47 per share. No future ex-date is on file yet.What are analysts saying about SNN?
Smith & Nephew SNATS Inc. has had 8 recent analyst actions on file. The most recent action was from Kepler: Hold on 2026-06-04. Recent price targets cluster around $3750.00.What companies are similar to SNN?
Notable peers in the same industry include ISRG (Intuitive Surgical Inc.), EW (Edwards Lifesciences Corporation), STE (STERIS plc (Ireland)), ZBH (Zimmer Biomet Holdings Inc.), MAS (Masco Corporation). Compare SNN side-by-side with any of them on Quantisnow.How can I track SNN on Quantisnow?
Quantisnow aggregates Smith & Nephew SNATS Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SNN to receive live email and push alerts on every new disclosure.